CLINICAL TRIALS AND OBSERVATIONS Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

نویسندگان

  • Renier J. Brentjens
  • Isabelle Rivière
  • Jae H. Park
  • Marco L. Davila
  • Xiuyan Wang
  • Jolanta Stefanski
  • Clare Taylor
  • Raymond Yeh
  • Shirley Bartido
  • Oriana Borquez-Ojeda
  • Malgorzata Olszewska
  • Yvette Bernal
  • Hollie Pegram
  • Mark Przybylowski
  • Daniel Hollyman
  • Yelena Usachenko
  • Domenick Pirraglia
  • James Hosey
  • Elmer Santos
  • Elizabeth Halton
  • Peter Maslak
  • David Scheinberg
  • Joseph Jurcic
  • Mark Heaney
  • Glenn Heller
  • Mark Frattini
  • Michel Sadelain
چکیده

*Renier J. Brentjens,1-3 *Isabelle Rivière,1-4 Jae H. Park,1,2 Marco L. Davila,1,2 Xiuyan Wang,2-4 Jolanta Stefanski,2-4 Clare Taylor,2-4 Raymond Yeh,1,2 Shirley Bartido,2,3 Oriana Borquez-Ojeda,2-4 Malgorzata Olszewska,2-4 Yvette Bernal,1 Hollie Pegram,1,2 Mark Przybylowski,2-4 Daniel Hollyman,2-4 Yelena Usachenko,1,2 Domenick Pirraglia,2-4 James Hosey,2-4 Elmer Santos,3,5 Elizabeth Halton,1 Peter Maslak,1 David Scheinberg,1-3 Joseph Jurcic,1 Mark Heaney,1 Glenn Heller,6 Mark Frattini,1 and Michel Sadelain1-3

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Second-line chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplantation (ASCT) cures less than half of the patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Prognostic models capable of predicting outcome are essential. In 3 sequential clinical trials, conducted from January 1993 to August 2000, we treated 150 patients with relapsed or pr...

متن کامل

CLINICAL TRIALS AND OBSERVATIONS Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)

We have investigated the in vivo safety, efficacy, and persistence of autologous Epstein Barr virus (EBV)–specific cytotoxic T lymphocytes (CTLs) for the treatment of solid organ transplant (SOT) recipients at high risk for EBV-associated posttransplantation lymphoproliferative disease (PTLD). EBV-CTLs generated from 35 patients expanded with normal kinetics contained both CD8 and CD4 lymphocyt...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Aerosolized Amphotericin B Inhalations as Prophylaxis of Invasive Aspergillus Infections During Prolonged Neutropenia: Results of a Prospective Randomized Multicenter Trial

We performed a prospective, randomized, multicenter trial to evaluate the effectiveness of prophylactic inhalations with aerosolized amphotericin B (aeroAmB) to reduce the incidence of invasive aspergillus (IA) infections in patients after chemotherapy or autologous bone marrow transplantation and an expected duration of neutropenia of at least 10 days. From March 1993 until April 1996, 382 pat...

متن کامل

Plenary Paper CLINICAL TRIALS AND OBSERVATIONS Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

• Depletion of host regulatory T cells with IL2DT improves efficacy of haploidentical NK cell therapy for refractory acute myeloid leukemia. • Depletion of Treg and persistence of NK cells for $7 days after NK cell adoptive transfer predicts beneficial clinical responses. Haploidentical natural killer (NK) cell infusions can induce remissions in some patients with acute myeloid leukemia (AML) b...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 in...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2011